Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4.
HSP
PPMS
SPG4
Serum GFAP
Serum NfL
biomarkers
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
03 Nov 2022
03 Nov 2022
Historique:
received:
26
09
2022
revised:
26
10
2022
accepted:
28
10
2022
entrez:
11
11
2022
pubmed:
12
11
2022
medline:
15
11
2022
Statut:
epublish
Résumé
In patients with slowly progressive spastic paraparesis, the differential diagnosis of primary progressive multiple sclerosis (PPMS) and hereditary spastic paraplegia (HSP) can be challenging. Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) are promising fluid biomarkers to support the diagnostic workup. Serum NfL is a marker of neuroaxonal decay sensitive to temporal changes, while elevated sGFAP levels may reflect astrocytal involvement in PPMS. We assessed sNfL and sGFAP levels in 25 patients with PPMS, 25 patients with SPG4 (the most common type of HSP) and 60 controls, using the highly sensitive single-molecule array (Simoa) platform. Patients were matched in age, sex, age at onset, disease duration and disease severity. Serum NfL levels were significantly increased in PPMS compared to SPG4 (
Identifiants
pubmed: 36362248
pii: ijms232113466
doi: 10.3390/ijms232113466
pmc: PMC9657281
pii:
doi:
Substances chimiques
Glial Fibrillary Acidic Protein
0
Neurofilament Proteins
0
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIH HHS
ID : 5R01NS072248
Pays : United States
Organisme : CReATe consortium
ID : U54NS092091
Organisme : TreatHSP network
ID : 01GM1905
Références
Hum Mutat. 2002 Aug;20(2):127-32
pubmed: 12124993
Hum Mol Genet. 2003 Jan 1;12(1):71-8
pubmed: 12490534
Lancet Neurol. 2022 Mar;21(3):246-257
pubmed: 35182510
J Neurol. 2019 May;266(5):1182-1193
pubmed: 30820738
PLoS One. 2017 Aug 10;12(8):e0182647
pubmed: 28797088
Brain. 2018 Aug 1;141(8):2382-2391
pubmed: 29860296
Ann Clin Transl Neurol. 2022 Mar;9(3):326-338
pubmed: 35171517
Neurology. 2019 Mar 5;92(10):e1007-e1015
pubmed: 30737333
Ann Neurol. 2016 Apr;79(4):646-58
pubmed: 26856398
eNeurologicalSci. 2018 Jul 04;12:42-46
pubmed: 30229136
J Neurol. 2011 May;258(5):882-8
pubmed: 21197541
Lancet Neurol. 2007 Oct;6(10):903-12
pubmed: 17884680
Hum Mol Genet. 2014 May 15;23(10):2527-41
pubmed: 24381312
J Neurol Neurosurg Psychiatry. 2019 Aug;90(8):870-881
pubmed: 30967444
N Engl J Med. 2017 Jan 19;376(3):209-220
pubmed: 28002688
Arch Neurol. 2002 Feb;59(2):281-6
pubmed: 11843700
Mult Scler. 2020 Feb;26(2):210-219
pubmed: 30570436
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Front Neurol. 2019 Mar 26;10:280
pubmed: 30972011
Brain. 2009 May;132(Pt 5):1175-89
pubmed: 19339255
Nat Med. 2014 Oct;20(10):1147-56
pubmed: 25216636
Nature. 2021 Sep;597(7878):709-714
pubmed: 34497421
Hum Mol Genet. 2000 Mar 1;9(4):637-44
pubmed: 10699187
Ann Clin Transl Neurol. 2021 May;8(5):1122-1131
pubmed: 33819388
Sci Rep. 2020 Jul 2;10(1):10923
pubmed: 32616916
Front Immunol. 2019 Jan 10;9:3116
pubmed: 30687321
Ann Clin Transl Neurol. 2018 May 21;5(7):876-882
pubmed: 30009206
J Neurol. 2020 May;267(5):1420-1430
pubmed: 32002649
Sci Rep. 2018 Oct 4;8(1):14798
pubmed: 30287870
Nat Rev Neurol. 2022 Mar;18(3):158-172
pubmed: 35115728
Mult Scler. 2019 Jan;25(1):15-17
pubmed: 30136895
Front Neurol. 2018 Dec 14;9:1037
pubmed: 30631300
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
EMBO Mol Med. 2020 Jul 7;12(7):e11803
pubmed: 32510847